LAS VEGAS, July 14, 2014 /PRNewswire/ -- BioAdaptives, Inc. (OTCBB:BDPT) is pleased to announce Mr. Barry Epling, Chairman has assumed the roles of President and CEO of the Company. Mr. Epling is the owner of Ferris Holding, Inc., the company that licensed its formulation, intellectual properties, and other technologies to BioAdaptives, Inc. and its financial supporter.
"Mr. Gerald Epling, who has been overseeing BioAdaptives from our early transition as a privately held entity to a public company, has decided to return to the private sector to concentrate on other interests," said Mr. Barry Epling, who went on to say, "We appreciate the dedication of Gerald Epling to the Company and his contributions, he will be missed."
Mr. Barry Epling added, "Due to the success of the human clinical trial on our stem cell activating product and the acceptance in test markets both in the United States and overseas, a stronger involvement under my direct supervision is required. These positive results suggest a number of avenues should be explored to develop a family of products to further the success of the company and offer significant benefits to both humans and animals."
About BioAdaptives, Inc.
BioAdaptives, Inc. is a fully-reporting public company trading on the OTC Bulletin Board under the symbol BDPT. The company is engaged in research and development in science-based nutraceutical products for both human and animal consumption. The company's focus, in conjunction with Ferris Holding, Inc., is to source high quality, unique raw material worldwide and develop science-based products to improve health and wellness for both humans and animals. It has also developed a proprietary method that is a non-intrus
|SOURCE BioAdaptives, Inc.|
Copyright©2014 PR Newswire.
All rights reserved